NASDAQ:PACB - Pacific Biosciences Stock Price, Price Target & More

Pacific Biosciences trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences (NASDAQ:PACB) announced its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to analysts' expectations of $23.97 million. Pacific Biosciences had a negative net margin of 105.22% and a negative return on equity of 91.11%. The company's quarterly revenue was down 22.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.26) EPS. View Pacific Biosciences' Earnings History.

Pacific Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences.

2 Wall Street analysts have issued 12 month target prices for Pacific Biosciences' stock. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences' share price to reach $5.40 in the next twelve months. View Analyst Ratings for Pacific Biosciences.

Some companies that are related to Pacific Biosciences include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Headlines about PACB stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacific Biosciences earned a media sentiment score of 0.03 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 48.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Pacific Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.67%), Blackstone Group L.P. (3.13%), Point72 Asset Management L.P. (1.59%), Northern Trust Corp (1.00%), Trellus Management Company LLC (0.59%) and Schwab Charles Investment Management Inc. (0.39%). View Institutional Ownership Trends for Pacific Biosciences.

PACB stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Pacific Biosciences.

PACB stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Blackstone Group L.P., BlackRock Inc., Citadel Advisors LLC, Millennium Management LLC, UBS Group AG, Trellus Management Company LLC and Northern Trust Corp. View Insider Buying and Selling for Pacific Biosciences.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $2.61.

Pacific Biosciences has a market capitalization of $344.20 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences employs 456 workers across the globe.

Pacific Biosciences' mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]